-

Bruce Booth is a Partner at Atlas Venture focused on helping start and fund emerging biotech therapeutics companies. He's married to a wonderful woman and has three great kids. Active skier, runner, fly fisherman.
-
subscribe by email
twitter
- $PTLA Portola IPO hailed as opening of window? Raised $320M privately, $122M IPO. So sitting at ~1x on avg at $0.5B mkt cap. Tough window. 6 hours ago
- Thx 4 RTs/comments on the blog: Mythbusting six perceptions about Biotech Venture Capital, ICYMI http://t.co/CUVdhbTSv8 10 hours ago
- Debunking 6 Myths About Biotech Venture Capital. Using data to confront a few misperceptions plus other observations http://t.co/CUVdhbTSv8 1 day ago
- MRK $5B stock buyback. R there not better uses? Acq things like Instagram & Tumblr 2 improve R&D visualization & micro-blogging study repts? 2 days ago
Recent Posts
current comments
- Nicholas Anderson on Debunking Myths About Biotech Venture Capital
- Carlos N Velez/Lacerta Bio on Debunking Myths About Biotech Venture Capital
- Joshua Anderson on Debunking Myths About Biotech Venture Capital
- k bosley on Debunking Myths About Biotech Venture Capital
- Jay Caplan on Debunking Myths About Biotech Venture Capital
topics
- Atlas Venture (2)
- Biotech financing (11)
- Biotech investment themes (13)
- Biotech startup advice (8)
- Boston Cluster (7)
- Capital efficiency (13)
- Diagnostics (2)
- Exits IPOs M&As (30)
- General Venture Capital (26)
- New business models (14)
- Personalized Medicine (2)
- Pharma industry (23)
- Portfolio news (10)
- Translational research (3)
- Uncategorized (12)
- VC-backed Biotech Returns (34)
Monthly Archive
- May 2013 (4)
- April 2013 (2)
- March 2013 (4)
- February 2013 (1)
- January 2013 (3)
- December 2012 (3)
- November 2012 (4)
- October 2012 (3)
- September 2012 (4)
- August 2012 (3)
- July 2012 (3)
- June 2012 (4)
- May 2012 (3)
- April 2012 (2)
- March 2012 (3)
- February 2012 (3)
- January 2012 (6)
- December 2011 (4)
- November 2011 (4)
- October 2011 (3)
- September 2011 (4)
- August 2011 (3)
- July 2011 (4)
- June 2011 (4)
- May 2011 (5)
- April 2011 (8)
- March 2011 (10)
Monthly Archives: August 2012
Biotech’s Capital Intensity Challenge: A Post-Mortem on 2007’s Biggest Deals
August 29, 2012
“Raise all the money you can whenever you can, and then raise some more”. “The more a company raises, the more successful it is”. Resumes boasting about how much an executive has raised in their prior companies. These sentiments are
Big BioPharma Stock Buybacks: Are There Better Alternatives?
August 22, 2012
Big Pharma remains a highly profitable cash cow in spite of its well-known R&D challenges and perennial patent cliffs. One of the biggest questions their Boards must wrestle with is what to do with all the cash. In recent years,
The Quiet Outperformance of Recent Biotech IPOs
August 1, 2012
Biotech IPOs have long been viewed with skeptism, especially over the past few years in comparison to the high-flying media darlings in the Tech space. But recently a number of the social media phenoms have fallen from grace: Groupon is



